Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Apr 9, 2025 | Press Releases

-Phio’s lead clinical siRNA compound PH-762 demonstrates supportive safety profile in third cohort, permitting escalation in next dose concentrationMarlborough, Massachusetts–(April 9, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a...

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Apr 3, 2025 | Press Releases

To be presented at 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany Marlborough, Massachusetts–(Newsfile Corp. – April 3, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biotechnology company...

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Mar 31, 2025 | Press Releases

Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-7623rd Cohort now fully enrolled in on-going clinical studyMarlborough, Massachusetts–(Newsfile Corp. – March 31, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a...

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical’s Clinical Research at 2025 Annual Meeting

Mar 10, 2025 | Press Releases

Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research SessionMarlborough, Massachusetts–(Newsfile Corp. – March 10, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company...

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Mar 5, 2025 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – March 5, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the...